Final answer:
Phenylbutazone reduces the elimination of warfarin, leading to an increase in warfarin plasma concentration. It highlights the role of pharmacogenomics in optimizing warfarin therapy and the potential for developing new drugs to manage anticoagulation.
Step-by-step explanation:
The question pertains to the interaction between phenylbutazone and warfarin. Phenylbutazone is known to affect the metabolism of certain drugs including warfarin, which is used as an anticoagulant to prevent blood clots. Specifically, phenylbutazone can reduce the elimination of warfarin from the body, thus increasing warfarin plasma concentrations. This can potentiate the effect of warfarin and increase the risk of bleeding, indicating that the correct answer to the question is option D: Phenylbutazone reduces the elimination of warfarin.
Pharmacogenomics can play a crucial role in individualizing drug therapy, especially for drugs like warfarin that have a narrow therapeutic index and are influenced by genetic factors. It can help in predicting drug response and adjusting the dosage to minimize the risk of overdose and adverse effects. Moreover, pharmacogenomics may contribute to the development of new drugs that could act as better alternatives or counteract the effects of existing medications such as Coumadin (warfarin).